A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Gemcitabine (Primary) ; Hydroxychloroquine (Primary) ; Ipilimumab (Primary) ; NG 350A (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms REVOLUTION
- 04 Jun 2024 Results of cohorts A and B presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 25 Oct 2023 Planned End Date changed from 11 Jan 2024 to 11 Jan 2025.
- 25 Oct 2023 Planned primary completion date changed from 11 Oct 2023 to 31 Oct 2024.